Previous close | 0.0300 |
Open | 0.0200 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 120.00 |
Expiry date | 2024-06-21 |
Day's range | 0.0200 - 0.0300 |
Contract range | N/A |
Volume | |
Open interest | 13 |
Bristol Myers (BMY) announces positive data from three studies evaluating CAR T cell therapy Breyanzi (liso-cel) and three updated analyses on studies evaluating Opdivo at ASCO.
Bristol Myers (BMY) announces positive data from three studies evaluating CAR T cell therapy Breyanzi (liso-cel) and three updated analyses on studies evaluating Opdivo at ASCO.
PRINCETON, N.J., June 04, 2024--Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or....